About: Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.89 (+1.05%)
VRCA NASDAQ Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc share price
Atividade de preço de VRCA
Último preço
$ 2,890
Variação (24h)
0,03 USD (1,05%)
Volume
77.97K
Volume (média 4 sem.)
-
Abertura
$ 2,95
Variação do dia
$ 2,78 - $ 3,18
Fechamento anterior
$ 2,86
Último negócio
19 Nov, 9:00 pm GMT+0
Atrasado
19 Nov, 9:00 pm GMT+0
VRCA price performance
Atrasado
19 Nov, 9:00 pm GMT+0
VRCA details
quote.marketSignals